Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/23278

Type
Article
Copyright
Open access
Collections
Share

Statistics
Metadata
Show full item record

TREATMENT AS PREVENTION: CHARACTERIZATION OF PARTNER INFECTIONS IN THE HIV PREVENTION TRIALS NETWORK 052 TRIAL
Eshleman, Susan H. et al. | Date Issued: 2017
Author
Eshleman, Susan H.
Hudelson, Sarah E.
Redd, Andrew D.
Swanstrom, Ronald
Ou, San-San
Zhang, Xinyi Cindy
Ping, Li-Hua
Piwowar-Manning, Estelle
Porcella, Stephen F.
Sievers, Matthew F.
Martens, Craig A.
Bruno, Daniel
Dukhovlinova, Elena
McCauley, Marybeth
Ganble, Theresa
Fogel, Jessica M.
Sabin, Devin
Quinn, Thomas C.
Gunde, Laurence
Maliwichi, Madalitso
Nhando, Nehemiah
Akelo, Victor
Moyo, Sikhulile
Panchia, Ravindre
Kumarasamy, Nagalingeswaran
Chotirosniramit, Nuntisa
Melo, Marineide Gonçalves de
Pilotto, José
Grinsztejn, Beatriz
Mayer, Kenneth
Chen, Ying Q.
Hughes, James P.
Cohen, Myron S.
Affilliation
Johns Hopkins University School of Medicine. Departments of Pathology. Baltimore, USA.
Johns Hopkins University School of Medicine. Departments of Pathology. Baltimore, USA.
National Institute of Health. NIAID. Laboratory of Immunoregulation. Baldtimore, MD, USA.
University of North Carolina at Chapel Hill. Department of Biochemistry and Biophysics. Chapel Hill, NC, USA.
Fred Hutchinson Cancer Research Institute. Vaccine and Infectious Disease Science Division. Seatle, VA, USA.
Fred Hutchinson Cancer Research Institute. Vaccine and Infectious Disease Science Division. Seatle, VA, USA.
University of North Carolina at Chapel Hill. Lineberger Comprehensive Cancer Center. Chapel Hill, NC, USA.
Johns Hopkins University School of Medicine. Departments of Pathology. Baltimore, USA.
National Institute of Health. NIAID. Genomics Unit. Research Technologies Section. Rocky Mountain Laboratories, DIR. Hamilton, MT, USA.
Johns Hopkins University School of Medicine. Department of Medicine. Baltimore, MD, USA.
National Institute of Health. NIAID. Genomics Unit. Research Technologies Section. Rocky Mountain Laboratories, DIR. Hamilton, MT, USA.
National Institute of Health. NIAID. Genomics Unit. Research Technologies Section. Rocky Mountain Laboratories, DIR. Hamilton, MT, USA.
University of North Carolina at Chapel Hill. Lineberger Comprehensive Cancer Center. Chapel Hill, NC, USA.
Science Facilitation Department. FHI360, Washington, DC.
Johns Hopkins University School of Medicine. Departments of Pathology. Baltimore, USA.
Johns Hopkins University School of Medicine. Departments of Pathology. Baltimore, USA.
National Institute of Health. NIAID. Laboratory of Immunoregulation. Baldtimore, MD, USA.
College of Medicine. ohns Hopkins Project, Blantyre, Malawi.
UNC Project. Lilongwe, Malawi.
University of Zimbabwe. Department of Medicine. Harare, Zimbabwe.
HIV Research Branch. Center for Global Health. Kenya Medical Research Institute. Centers for Disease Control, Kisumu, Kenya.
Botswana Harvard AIDS Institute Partnership. BHHRL & Clinical Trials Unit. Gaborone, Botswana.
Chris Hani Baragwanath Hospital. Soweto HPTN CRS. Soweto, South Africa.
YRGCARE Medical Centre. Chennai, India.
Chiang Mai University. Research Institute for Health Science. Center for AIDS and STDs. Chiang Mai, Thailand.
Hospital Nossa Senhora da Conceição. Serviço de Infectologia,. Porto Alegre, RS, Brasil
Hospital Geral de Nova Iguaçu. Nova Iguaçu, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de AIDS e Imunologia Molecular. Rio de Janeiro, RJ, Brasil
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
The Fenway Institute. Fenway Health and Infectious Disease Division. Boston, MA, USA / Harvard Medical School, Beth Israel Deaconess Medical Center. Department of Medicine. Boston, MA. USA.
Fred Hutchinson Cancer Research Institute. Vaccine and Infectious Disease Division and Public Health Science Division. Seatlle, WA, USA.
Fred Hutchinson Cancer Research Institute. Department of Biostatistics. Seattle, WA, USA.
University of North Carolina at Chapel Hill. Department of Medicine. Chapel Hill, North Carolina, USA.
Abstract
HIV Prevention Trials Network 052 demonstrated that antiretroviral therapy (ART) prevents HIV transmission in serodiscordant couples. HIV from index-partner pairs was analyzed to determine the genetic linkage status of partner infections. Forty-six infections were classified as linked, indicating that the index was the likely source of the partner's infection. Lack of viral suppression and higher index viral load were associated with linked infection. Eight linked infections were diagnosed after the index started ART: 4 near the time of ART initiation and 4 after ART failure. Linked infections were not observed when the index participant was stably suppressed on ART.
Keywords in Portuguese
HIV-1
Transmissão
Ligação
Casais serodiscordantes
 
Keywords
HIV-1
Serodiscordant couples
Partner
Transmission
Linkage
HPTN 052
 
Publisher
Lippincott, Williams & Wilkins
Citation
ESHLEMAN, Susan H. et al. Treatment as Prevention: Characterization of Partner Infections in the HIV Prevention Trials Network 052 Trial. Journal of Acquired Immune Deficiency Syndromes, v. 74, n. 1, p. 112-116, Jan. 2017.
DOI
10.1097/QAI.0000000000001158
ISSN
1525-4135